Insider transaction details
Director Tariq Musa of Guardant Health, Inc. (NASDAQ:GH) disposed of 116 shares of the company's common stock on April 16, 2026. The shares were sold at $84.83 each, resulting in an aggregate transaction value of $9,840.
According to a Form 4 filing submitted to the Securities and Exchange Commission, Musa also exercised options on 250 shares of Restricted Stock Units at a price of $0 on April 15. Following those transactions, Musa's direct ownership in Guardant Health stands at 8,528 shares.
Context from company financials and analyst moves
These insider moves coincide with recent attention to Guardant Health's financial disclosures and analyst coverage. The company reported fourth-quarter 2025 results that included $35.1 million in Shield revenue, a figure that the company said was in line with its prior preannouncement.
Brokerage and research houses have been active on the stock. Piper Sandler reiterated an Overweight rating and kept a $130 price target, citing supportive clinical trial data. TD Cowen revised its price target down to $120 from $135 while maintaining a Buy rating and projecting first-quarter sales of $306 million, a forecast the firm said is slightly below consensus estimates.
Stifel raised its price target to $130, pointing to the company's guidance and operational approach. Canaccord Genuity also increased its price target to $135, attributing the change to higher revenue assumptions in its long-term model and reiterating a Buy rating after discussions on Guardant Health's cancer screening initiatives.
Key points
- Tariq Musa sold 116 shares on April 16, 2026, at $84.83 per share, totaling $9,840.
- On April 15, Musa exercised options on 250 shares of Restricted Stock Units at a price of $0; he now directly owns 8,528 shares.
- Guardant Health reported $35.1 million in Shield revenue for Q4 2025 and has seen multiple analyst price-target and rating updates.
Risks and uncertainties
- Analyst estimates and price-target changes indicate differing views on near-term revenue and growth - this creates uncertainty for investors in the healthcare and biotech sectors.
- Forecasts such as TD Cowen's projected first-quarter sales of $306 million, which the firm notes are slightly below consensus, highlight potential volatility in expected top-line performance for Guardant Health and related market valuations.
This report presents the transactions and related analyst commentary as disclosed. It does not draw conclusions beyond the facts reported in the filing and the firms' stated views.